α-type-1 polarized dendritic cells: A novel immunization tool with optimized CTL-inducing activity

Cancer Research

Volumn 64, Issue 17, 2004, Pages 5934-5937

  Mailliard, Robbie B ^a   Wankowicz Kalinska, Anna ^a   Cai, Quan ^a   Wesa, Amy ^a   Hilkens, Catharien M ^d   Kapsenberg, Martien L ^e   Kirkwood, John M ^b,f   Storkus, Walter J ^a,c,f   Kalinski, Pawel ^a,b,c,f  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESCHERICHIA COLI LIPOPOLYSACCHARIDE; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; MELAN A; MELANOMA ANTIGEN; MONOPHENOL MONOOXYGENASE; POLYINOSINIC POLYCYTIDYLIC ACID; PROSTAGLANDIN E2; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 1BETA; RECOMBINANT INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 7; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; CHEMOTAXIS; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOSTIMULATION; MONONUCLEAR CELL; PRIORITY JOURNAL;

CELL POLARITY; CHEMOTAXIS; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; INTERFERON-ALPHA; INTERLEUKIN-1; INTERLEUKIN-12; LIGANDS; MELANOMA; POLY I-C; PROTEIN SUBUNITS; RECEPTORS, CHEMOKINE; T-LYMPHOCYTES, CYTOTOXIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4344596051     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1261     Document Type: Article

References (19)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature (Lond) 1998;392(6673):245-52.
2. Engleman EG. Dendritic cell-based cancer immunotherapy. Semin Oncol 2003; 30(3Suppl 8):23-9.
3. Albert ML, Jegathesan M, Darnell RB. Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells. Nat Immunol 2001;2:1010-7.
4. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001;193:233-8.
5. Dieu MC, Vanbervliet B, Vicari A, et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 1998;188:373-86.
6. Zjtvogel L, Mayordomo JI, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996;183:87-97.
7. Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res 1999;59:4035-41.
8. + t cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol 2003;171:2251-61.
9. Kalinski P, Schuitemaker JH, Hilkens CM, Wierenga EA, Kapsenberg ML. Final maturation of dendritic cells is associated with impaired responsiveness to IFN-γ and to bacterial IL-12 inducers: decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells. J Immunol 1999;162:3231-6.
10. Langenkamp A, Messi M, Lanzavecchia A, Sallusto F. Kinetics of dendritic cell activation: impact on priming of Th1, Th2 and nonpolarized T cells. Nat Immunol 2001;1:311-6.
11. Vieira PL, de Jong EC, Wierenga EA, Kapsenberg ML, Kalinski P. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol 2000;164:4507-12.
12. Jonuleit H, Kuhn U, Muller G, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997;27:3135-42.
13. de Jong EC, Vieira PL, Kalinski P, et al. Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse Th cell-polarizing signals. J Immunol 2002;168:1704-9.
14. Scandella E, Men Y, Gillessen S, Forster R, Groettrup M. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 2002;100:1354-61.
15. Luft T, Jefford M, Luetjens P, et al. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E2 regulates the migratory capacity of specific DC subsets. Blood 2002;100:1362-72.
16. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32.
17. Honda K, Sakaguchi S, Nakajima C, et al. Selective contribution of IFN-α/β signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection. Proc Natl Acad Sci USA 2003;100:10872-7.
18. Takaoka A, Mitani Y, Suemori H. Cross talk between interferon-gamma and -alpha/beta signaling components in caveolar membrane domains. Science (Wash DC) 2000;288:2357-60.
19. Harcourt JL, Offermann MK. Multiple signaling cascades are differentially involved in gene induction by double stranded RNA in interferon-alpha-primed cells. Eur J Biochem 2001;268:1373-81.